Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you stop Wegovy, the appetite-suppressing effects of semaglutide gradually wear off over several weeks. Most people find hunger returns, food feels less filling, and body weight tends to creep back up — sometimes substantially. This is not a sign of failure; it reflects the biology of how the medicine works. Wegovy is a prescription-only medicine, and any decision to stop should be discussed with the prescriber who reviews your treatment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Maybe the side effects have been harder to manage than you expected. Maybe the cost has become a strain, or life has simply shifted. Whatever brought you to this page, the question is a fair one, and the honest answer is that stopping Wegovy has real, predictable consequences that are worth understanding before you make a final call.
Semaglutide works by activating GLP-1 receptors in the brain and gut, slowing gastric emptying and reducing appetite. While you are on it, that signal is continuous. When you stop, the medicine clears from your system over a few weeks, and the signal fades with it. Your appetite does not stay where it was during treatment; for most people it returns to roughly where it was before. The NHS medicines page for semaglutide notes this directly, explaining that weight management medicines are usually taken long term because obesity is a chronic condition.
That framing matters. Weight tends to return not because of anything you did wrong, but because the biological mechanism that was helping regulate your appetite is no longer active. Hunger, portion satisfaction and food reward all behave differently once the medicine is gone.
The STEP 1 extension study followed participants after they completed the main 68-week trial. One year after stopping semaglutide 2.4mg, average body weight had returned to within about 5 percentage points of the original starting weight, meaning most of the roughly 15% average loss seen during the trial had reversed. That is a substantial finding, and it is one reason the clinical conversation around GLP-1 medicines has shifted toward thinking about them as long-term treatments rather than short courses.
The STEP 1 trial, published in the New England Journal of Medicine, is the primary evidence base here. The regain data were published in a follow-up paper but draw on the same cohort, worth knowing if you want to read the primary research yourself.
It is also worth reading through what happens when you stop taking Wegovy in more detail, including the timeline of how quickly effects change, which varies between people. For a broader look at the longer-term picture, our page covering what happens after you stop Wegovy goes into where patients typically end up over time, including how appetite and weight trajectory tend to evolve in the months that follow.
There is no clinical evidence that semaglutide requires a formal taper the way some medicines do) the dose schedule exists for tolerability on the way up, not because abrupt stopping causes a withdrawal syndrome. That said, if you are stopping because of side effects, a prescriber may suggest remaining at a lower dose for longer rather than coming off entirely, particularly if the side effects are GI-related and linked to a recent dose increase.
The bigger practical point is this: stopping is a decision your prescriber should know about. At nume, every repeat order goes through a fresh clinical review (a real clinician reads your responses, not software) so there is already a natural moment to raise concerns. If something is making you consider stopping, that conversation is exactly what the review is for. You can also reach the clinical team directly through our contact page.
If you are on Wegovy through a different provider and considering stopping, the same applies: talk to whoever prescribed it. The NHS England guidance on weight management injections recommends that treatment decisions, including discontinuation, are made with clinical support rather than unilaterally.
Stopping does not close any doors permanently. Some people pause treatment intentionally (around surgery, during pregnancy planning, or through a financial squeeze) and restart when circumstances change. Others move to a different medicine. A small number find that the habits built during treatment help them maintain enough of their progress without continuing.
If you are thinking about what stopping might mean for you specifically, it helps to look at the full picture of how Wegovy works alongside the regain data, rather than making the decision in either direction on incomplete information. For those who stopped and are wondering whether to restart or switch, our guide to what happens when you stop using Wegovy addresses the restart question directly, including what to expect from your body in the weeks after your final dose.
There is also the option of exploring whether a different treatment might suit your situation better. Our weight-loss treatments overview sets out the options currently available, and if you want to talk through your own circumstances, checking your eligibility with our prescribers is the straightforward next step, free, with no commitment to proceed.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.